Intellectual property issues of immune checkpoint inhibitors

被引：8
作者：
Storz, Ulrich [1 ,2 ]
机构：
[1] Michalski, Dusseldorf, Germany
[2] Huttermann Patent Attorneys, Dusseldorf, Germany
来源：
MABS | 2016年 / 8卷 / 01期
关键词：
antibody; CTLA4; Immune checkpoint inhibitors; Keytruda; Opdivo; patent; PD1; PD-L1; Yervoy; B7; FAMILY; CTLA-4; ANTIBODIES; CP-675,206; MELANOMA; THERAPY; MEMBER; B7-H1; PD-1;
D O I：
10.1080/19420862.2015.1107688
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.
引用
收藏
页码：10 / 26
页数：17
相关论文
共 50 条
  • [21] Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases
    Di Nunno, Vincenzo
    Nuvola, Giacomo
    Mosca, Mirta
    Maggio, Ilaria
    Gatto, Lidia
    Tosoni, Alicia
    Lodi, Raffaele
    Franceschi, Enrico
    Brandes, Alba Ariela
    IMMUNOTHERAPY, 2021, 13 (05) : 419 - 432
  • [22] How we treat endocrine complications of immune checkpoint inhibitors
    Paschou, S. A.
    Stefanaki, K.
    Psaltopoulou, T.
    Liontos, M.
    Koutsoukos, K.
    Zagouri, F.
    Lambrinoudaki, I
    Dimopoulos, M-A
    ESMO OPEN, 2021, 6 (01)
  • [23] Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
    Zeng, Zhu
    Yang, Biao
    Liao, Zheng-Yin
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [24] Vasculitis associated with immune checkpoint inhibitors-a systematic review
    Daxini, Anisha
    Cronin, Keri
    Sreih, Antoine G.
    CLINICAL RHEUMATOLOGY, 2018, 37 (09) : 2579 - 2584
  • [25] Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
    Gjoerup, Ole
    Brown, Charlotte A.
    Ross, Jeffrey S.
    Huang, Richard S. P.
    Schrock, Alexa
    Creeden, James
    Fabrizio, David
    Tolba, Khaled
    AAPS JOURNAL, 2020, 22 (06)
  • [26] Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
    Olbryt, Magdalena
    Rajczykowski, Marcin
    Widlak, Wieslawa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 20
  • [27] Immune checkpoint inhibitors and endocrine side effects, a narrative review
    Agrawal, L.
    Bacal, A.
    Jain, S.
    Singh, V
    Emanuele, N.
    Emanuele, Ma
    Meah, F.
    POSTGRADUATE MEDICINE, 2020, 132 (02) : 206 - 214
  • [28] Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer
    Jin, Ke-Tao
    Wang, Shi-Bing
    Ying, Xiao-Jiang
    Lan, Huan-Rong
    Lv, Jie-Qing
    Zhang, Li-Hua
    Motallebnezhad, Morteza
    Mou, Xiao-Zhou
    IMMUNOLOGY LETTERS, 2020, 221 : 61 - 71
  • [29] Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
    Ouwerkerk, Wouter
    van den Berg, Mirjam
    van der Niet, Sanne
    Limpens, Jacqueline
    Luiten, Rosalie M.
    MELANOMA RESEARCH, 2019, 29 (05) : 453 - 464
  • [30] Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)
    Ruggeri, R. M.
    Campenni, A.
    Giuffrida, G.
    Trimboli, P.
    Giovanella, L.
    Trimarchi, F.
    Cannavo, S.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (07) : 745 - 756
12345